X-box binding protein 1 (XBP1) is a unique basic region leucine zipper transcription factor that was isolated two decades ago in a search for regulators of major histocompatibility complex class II gene expression. XBP1 is a very complex protein that regulates many physiological functions, including the immune system, inflammatory responses and lipid metabolism. Evidence over the past few years suggests that XBP1 also plays an important role in pathological settings, since its activity as a transcription factor has profound effects on the prognosis and progression of diseases such as cancer, neurodegeneration and diabetes. Here we provide an overview of recent advances in our understanding of this multifaceted molecule, particularly in regulating synaptic plasticity and memory function, and the implications in neurodegenerative diseases, with an emphasis on Alzheimer's disease.
between XBP1 and AD. We summarize recent evidence that local translation at the synapse may control XBP1 functional availability at dendritic spines. We review the data suggesting that XBP1 is protective against Aβ neurotoxicity and regulates memory function. Finally, we consider how these pieces might fit together to suggest a mechanism by which XBP1 alleviates pathology in AD and the implications moving forward from a therapeutic strategy standpoint.
Evidence for the Presence and Role of XBP1 in Dendritic spines
Synaptic connectivity and the dynamics of presynaptic (neurotransmitter release) and postsynaptic (receptor insertion and internalization) sites that regulate learning and memory processes are compromised in Alzheimer's disease (AD). Glutamate receptor-dependent synaptic plasticity is altered by exposure to oligomeric forms of Aβ peptide in different systems (for review, see (2)). Studies have shown extensively that Aβ oligomers cause morphological abnormalities in the dendrites as well as a significant reduction in spine density (3, 4) and induce memory deficits in naive mice (5) . Further, Aβ-induced loss of dendritic spines is a structural of dementia cost the US $226 billion in medical treatment, nursing home facility and other related costs. By 2050, the overall annual cost of treating AD could reach $1.1 trillion, making it more costly to address than other potentially deadly diseases like cancer and leukemia (according to a report published in 2015 by the Alzheimer's Association, titled "Changing the Trajectory of Alzheimer's Disease"). This review highlights some of the most recent developments in AD research involving X-box binding protein 1 (XBP1), a transcription factor associated with the endoplasmic reticulum stress response. We begin with a brief review of synaptic structure and the concept of dendritic spine loss in AD and provide an update regarding the link iNTRODUCTiON Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive and irreversible cognitive decline. It is the most common cause of dementia and affects over 44 million people worldwide. The molecular hallmarks of AD are amyloid plaques (extracellular deposits consisting of aggregated insoluble amyloid-β [Aβ]) and neurofibrillary tangles (intracellular filamentous aggregates of hyperphosphorylated tau) in brain regions critical for learning and memory function (1). The staggering financial impact on society associated with the direct and indirect costs of caring for those afflicted by AD make it urgent to find effective treatments. Indeed, in 2015 alone, Alzheimer's and other forms
The Transcription Factor XBP1 in Memory and Cognition: implications in Alzheimer's Disease abnormality that alters the function of a large number of signaling molecules at postsynaptic sites (2,6). Many of these molecules are critical elements responsible for shaping and maintaining anatomical structures on neurons and mediating signaling pathways that control neuronal communication. In recent years, numerous studies have identified several putative receptors for Aβ oligomers, including α7-nAChR (7), RAGE (8) , PrP c (9), mGluR5 (10, 11) , insulin receptor (12) , EphB2 receptor (13, 14) , human LilrB2 (15) , the p75 neurotrophic receptor (16) and reelin (17) . Interaction of Aβ oligomers with these receptors might constitute crucial events leading to morphological and functional changes of dendritic spines associated with cognitive impairment in AD (4, 18) . Thus, preserving the spines' dynamic and integrity is essential for the brain to develop synaptic networks capable of accurate information processing. Accordingly, tremendous efforts have been oriented toward therapeutic strategies aimed at circumventing Aβ neurotoxicity by activation of signaling pathways (13, 19, 20) that XBP1 exerts its beneficial effects in the brain through a regulatory loop involving IRE1α, XBP1 and BDNF. Generally consistent with the above findings, another study examined the role of XBP1 in the brains of naive mice and transgenic models of AD (19) . The report describes a preventive paradigm, as AD transgenic mice had no apparent synaptic and memory deficits at the time of intervention. At a later time point, measures of spine density, synaptic plasticity and hippocampal-dependent memory revealed significant improvements in AD mice expressing XBP1 relative to controls (19) . The remainder of the study focused on delineating the mechanisms by which changes at the level of dendritic spines occur throughout life and underlie structural mechanisms that control synaptic function and efficacy. There is evidence that spine density correlates with learning and memory performance (54, 55) . Dendritic spines are very dynamic structures with diverse shapes (56) that can be influenced by experimental manipulations. These manipulations trigger internal neuronal inputs from other brain regions or external environmental stimuli to impact their density, motility, morphology and activity in both physiological (57, 58) and pathological (19, 21) contexts. Synaptic changes related to neuronal activity have been extensively explored by using the enriched environment paradigm as a means to study the impact of neuritogenesis and spinogenesis on learning and memory performance (59) . Interestingly, genes involved in neuronal structure and synaptic plasticity, along with XBP1, were modulated by enrichment training (60) . The wealth of evidence indicating that XBP1 is involved in many physiological and pathological functions (27,28,61-68) is clearly at odds with the relatively small amount of attention it has received with regard to its role in memory function. As of this writing, only two studies have investigated the role of XBP1 in neuronal plasticity. In one study (26), Martinez et al. addressed two issues, the consequences of manipulating XBP1 expression in naive mice and the mechanism by which XBP1 exerts its effects in the brain. In the first set of studies, the authors assessed XBP1 function in the brain by taking advantage of two mouse models, a neural-specific Xbp1 conditional knockout model (XBP1 Nes-/-) (69) and a transgenic model (Tg XBP1s ) that expresses XBP1s in neurons exclusively (26). The behavior screen on XBP1
Nes-/-mice revealed poor performance relative to controls in diverse hippocampus-and amygdala-dependent memory tests. Moreover, long-term potentiation (LTP), a complex long-lasting form of plasticity involving Ca+/calmodulin-dependent protein kinase (70) , at Schaffer collaterals to pyramidal cell synapses was greatly regulate expression and activity of the aspartyl protease β-site APP cleaving enzyme 1 (BACE1) (42), the rate-limiting enzyme involved in the production of Aβ peptide (43) , by promoting the activity of the ubiquitin-ligase HRD1 (42) . Thus, this interplay might fuel a negative signaling loop with XBP1 reducing BACE1 and Aβ. Consequently, this further reduces BACE1 expression/activity, since Aβ has been shown to control BACE1 levels (42, (44) (45) (46) . However, one cannot exclude alternative signaling pathways involving p25/CDK5 (47) or LRP1 (48, 49) . Similarly, overexpression of ATF6 and XBP1 induced HDR1 expression and reduced APP levels in a proteasome-dependent manner, with a subsequent decrease in Aβ levels (50) . Together, these experimental findings support the notion that XBP1 influences Aβ levels, with subsequent neuroprotective effects. Consistent with this hypothesis, induction of DNJ-27, an ER luminal protein, by IRE1α/XBP1 ameliorates many deleterious phenotypes associated with Aβ peptides in a worm model of AD (51) . Another study reported that resveratrol, a polyphenol present in red wine, reduces Aβ1-42-induced toxicity through activation of XBP1 in an Alzheimer's model of Caenorhabditis elegans (52) . Moreover, XBP1 prevented the accumulation of free calcium by reducing a specific isoform of the ryanodine receptor in flies expressing Aβ and neurons treated with Aβ oligomers (53) . However, the full extent of how XBP1 exerts these beneficial effects and which molecular pathways are involved are poorly understood. Overall, this data coupled with the high expression of XBP1 in neuronal structures and its capacity to control genes involved in neuronal connectivity strongly suggests that it plays a central role in synaptic plasticity and memory function.
XBP1 Regulates Memory Function and Ameliorates AD-like Pathology
The hippocampus represents a major brain region in the systematic storage and organization of memories. Morphological XBP1 is beneficial in the brain and showed activation of Rho-GEF Kalirin-7 signaling, which has a major role in the regulation of synapse formation, maturation and maintenance by engaging Rac1 (71) (72) (73) . Interestingly, Kalirin-7, which is controlled by XBP1s transcriptional activity, was reduced in distinct animal models and human AD brains, more likely by Aβ-toxic species (19) . This observation is important because shRNA-mediated depletion of endogenous Kalirin-7 in naive mice recapitulated the main synaptic and memory deficits observed in the AD model, which supports an important role for XBP1s/Kalirin-7 signaling in neuronal plasticity and memory function under normal conditions. This notion is further supported by the observation that shRNA-mediated blockade of Kalirin-7 signaling prevented the beneficial effects of XBP1s in AD mice, whereas blockade of EphB2, which has a well-established functional connection with Kalirin-7 (74,75), had no effect. In contrast, direct delivery of EphB2 in the hippocampus rescued memory in the same paradigm (19) . Altogether, this suggests that Kalirin-7 mediates the beneficial effects exerted by XBP1 independently of EphB2. However, the possibility that XBP1 might be acting downstream of EphB2 remains to be determined. It should be pointed out that XBP1s, besides restoring spine density, lowered overall Aβ levels in the hippocampus as well (19) . In conclusion, this model implicates a dual mechanism wherein XBP1s synergistically promotes synaptic plasticity by fostering spine formation through Kalirin-7 signaling and lowers Aβ levels. Although the mechanisms underlying the XBP1s-dependent decrease of Aβ levels were not fully elucidated in that study, they may require recruitment and activation of enzymes that regulate Aβ levels (41, 42, (76) (77) (78) (79) and/or APP metabolism/trafficking (40, (80) (81) (82) .
Potential Mediators of XBP1 signaling in Neurons
Dendritic spines are morphologically and functionally highly heterogeneous (57) . Given the diversity of extrinsic and intrinsic factors controlling their structure, shape, dynamic, elimination and remodeling, it is not surprising that numerous molecules regulate their complex architecture and function (83, 84) . There are three main aspects of modulating synapse function: (1) promotion of synaptic transmission by enhancing transmitter release or blocking transmitter degradation and/or reuptake, (2) facilitation of synaptic plasticity by changing neuronal activity, and (3) stimulation of synaptogenesis by promoting the growth of new terminals or strengthening the existing pre-and postsynaptic structures by neurotrophic factors (85) . For instance, XBP1 modulates many molecules involved in spine morphogenesis and memory function, including but not limited to Cdk5 (24,86), BDNF (26) and Kalirin-7 (87). An interesting question that remains unresolved is whether those molecules are similarly activated by XBP1 and engaged through a sequential chain of events along the same signaling pathway. Alternatively, these proteins can be independently recruited and activated through different pathways based on the specific neuronal connection that is established and cellular activity that needs to be achieved. These possibilities are not mutually exclusive and might also depend on the nature and intensity of the neuronal stimulus and the complexity of the function that is initiated. Indeed, experimental evidence for the latter scenario has recently been obtained in an AD model, in which XBP1 activates Kalirin-7 to rescue spine density and memory while engaging an additional pathway that reduces Aβ levels (19) . These events seem to be controlled by XBP1 through two independent branches, because blockade of Kalirin-7 signaling induced spine loss and deficits in synaptic plasticity and memory but did not preclude Aβ reduction. Thus, maintaining spine integrity and functionality, not necessarily reducing the levels of oligomeric Aβ or other potential neurotoxins such as C99 (88) and tau (89) , is the sine qua non of neuronal plasticity and proper brain function in AD pathology. Furthermore, Aβ oligomers affect a myriad of proteins at synapses, some of which are of paramount importance to the structure and plasticity of dendritic spines. Consequently, therapies based solely on a toxin-reducing approach, without associating a synaptic repair strategy by rescuing these critical proteins, would most likely be unsuccessful, particularly later on in the syndrome, when their function is altered and the integrity of spines is compromised. This was made even more evident by reports of clinical studies that showed effective reduction of Aβ levels with concomitant reduction of amyloid plaque pathology but failed to improve the clinical outcome (90, 91) . However, this reasoning is an oversimplistic explanation of AD etiology, since one has to specifically target the neurotoxin that is the most likely determinant of the syndrome to significantly ameliorate the pathology. Indeed, AD is a syndrome that involves dysregulated homeostasis on various fronts, likely resulting from a complex interplay between genetic, epigenetic and environmental factors. Furthermore, major epigenetic mechanisms involving DNA methylation, DNA demethylation, noncoding RNAs and chromatin remodeling might mediate interactions between genetic and environmental risk factors or directly interact with disease-specific pathological factors in AD (92) (93) (94) .
Cdk5 is a member of the cyclindependent kinase family, which has been implicated in drug addiction, pain signaling, microtubule dynamics, and learning and memory formation (95, 96) . Cdk5 is abundant in neuronal cells and is activated by complexing with p35 or p39 protein. It was recently reported that Cdk5 is required for the development and maintenance of dendritic spines in the mouse hippocampus (97) . Furthermore, a conditional knockout mouse model of p35 exhibited spatial learning and memory impairments and reduced anxiety-like behavior through a cdk5-dependent pathway resulting from a decrease in the dendritic spine density of CA1 pyramidal neurons and defective stimulation (158) . Hence, one would expect a blockade of Kalirin-7 signaling to abolish the rescue of memory function elicited by BDNF (26). Alternatively, a disruption of BDNF signaling would likely reduce or prevent XBP1-dependent amelioration of AD-like pathology (19) . In vivo and in vitro studies have demonstrated that oligomeric Aβ alters BDNF expression/function by downregulating its transcripts or impairing axonal transport, with subsequent adverse effects (159) (160) (161) (162) (163) (164) (165) . Oligomeric Aβ also reduces BDNF secretion by dendritic cells in humans, thereby decreasing neurotrophic supports for neurons and causing brain damage (166) . An important aspect to consider is that expressing XBP1 in the brain promoted BDNF (26) or Kalirin-7 (19) signaling, with beneficial outcomes in spine density and memory. These observations led to the intuitive interpretation that XBP1 levels might be reduced in AD models and/or human patients. Surprisingly, endogenous XBP1 was undetectable in AD models that produced high levels of oligomeric Aβ or in human brains postmortem (19) , whereas neurons exposed to Aβ oligomers showed a significant increase of XBP1 levels (42, 167) . These discrepancies likely reflect a compensatory mechanism triggered by acute exposure to Aβ oligomers, whereas chronic exposure to these neurotoxins, which is more reflective of the in vivo situation, causes an overdrive and collapse of the system. Direct evidence for such fluctuations comes from a recent study showing transient XBP1 activation at early time points in pathology followed by a decrease across different ages and AD models, as well as in humans (41) . Notwithstanding the considerable knowledge of XBP1 biology, we do not yet know to what extent the various mediators of XBP1 signaling function through common, distinct or partly overlapping mechanisms. For that reason, future research efforts should determine the exact spatiotemporal sequence of events that controls XBP1-dependent amelioration of memory function and protection against AD-like phenotypes. neuronal atrophy and synapse loss in aged rats and nonhuman primates (137) . What is more, a human genetic polymorphism in the gene encoding BDNF has been linked to abnormal brain structure, hippocampal activity and memory in humans (138) (139) (140) and to several psychiatric disorders (141) (142) (143) (144) (145) . On a similar note, a polymorphism in the XBP1 promoter has been linked to a risk of AD (146) . Collectively, these findings indicate that BDNF exerts substantial protective effects on the neuronal circuitry involved in AD and deserves to be further investigated as a mediator of XBP1 signaling and a potent therapeutic target across many neurodegenerative disorders.
Kalirin-7 also participates in XBP1 signaling and memory formation (19) . In adults, Kalirin-7 is the major isoform in mature neurons, whereas Kalirin-9 and Kalirin-12 are primarily found at lower levels in peripheral tissues (87) . Genetic disruption of Kalirin-7 reduced spine density and induced several motor and behavior deficits (71, (147) (148) (149) . Depletion of Kalirin-7 also impairs synaptic plasticity, probably through alteration of glutamate receptors and Rac1 signaling (150, 151) . Rac1 is a downstream mediator of Kalirin-7 that controls the structural and functional plasticity of spines (152) (153) (154) and memory function (155, 156) . Intriguingly, a recent study described a three-molecule model in dendrites that characterizes the spatiotemporal coordination of Rac1, RhoA and Cdc42 controlling the structural plasticity (sLTP) of spines (157) . This model represents the BDNF-TrkB-Rac1 signaling that enables synaptic crosstalk during sLTP induction in spines. Although Kalirin-7 and BDNF have not been studied alongside each other with regard to memory function, evidence in the literature suggests that the two might be intricately linked through XBP1 activity-dependent regulation of spine plasticity. Indeed, BDNFdependent neurite outgrowth was abrogated by pharmacological blockade of TrkB or Kalirin-7 activity, and ablation of the Kalirin-7 gene abolished activation of Rac1 in response to BDNF long-term depression induction in the hippocampus (98) . Cdk5 also controls memory function via regulation of surface NR2B (99) . Importantly, TrkB phosphorylation-deficient mice displayed impaired spatial memory and compromised hippocampal LTP. These deficits were caused by an inability of TrkB receptors to be phosphorylated and interact with Rac1 for dendritic spine remodeling and reveals the importance of Cdk5 for LTP and spatial memory formation (86) . Interestingly, abnormal Cdk5 activity has been implicated in AD pathology (100) (101) (102) (103) .
On the other hand, XBP1 can promote neurite outgrowth in neurons (33,104) and enhance memory function in healthy mice (26) through regulation of BDNF, a member of the neurotrophin family (105) . BDNF is ubiquitously expressed in the brain and has a wide range of neurotrophic properties that are mediated by the TrkB receptor. BDNF regulates synaptic plasticity in the brain (106-111), which in turn promotes synaptic growth (112) (113) (114) . Interestingly, a report showed that the kinetics of TrkB activation by BDNF is a determining factor in cell signaling, with variable effects on spine structure and function (115) . More evidence obtained by using knockout models revealed that BDNF signaling positively influences synaptic growth by fostering synapse formation, axonal branching, spine motility and dendritic growth (116) (117) (118) (119) . These significant changes have profound and long-lasting effects on synaptic plasticity, learning and memory function. Indeed, genetic and/or pharmacological manipulations of either BDNF or TrkB levels impaired (120) (121) (122) (123) (124) (125) or ameliorated (126) (127) (128) (129) (130) neuronal plasticity and hippocampusdependent memory. BDNF has been implicated in a vast array of neurological disorders, including AD (85, (131) (132) (133) (134) (135) (136) . Interestingly, a recent study showed that BDNF delivered after disease onset reversed pathology in an AD model (137) . BDNF administration in the entorhinal cortex compensated for genetic, molecular and behavioral parameters of age-related mechanisms (179, 187) , gene therapy (19, (188) (189) (190) (191) (192) (193) and genetic depletion (6, 9, 194, 195) . These approaches have shown great efficacy, at least in experimental models, in restoring spine density and memory function. Therefore, a combination of factors that positively regulate spine dynamics and neuronal connectivity or block Aβ interaction with molecules that mediate its adverse effects could be efficient and should continue to be explored as a strategy to stop or delay cognitive decline in AD. For instance, future investigative steps should determine whether XBP1 is protective across various AD models and is as efficient in a curative paradigm. XBP1 can be activated upon administration of BDNF, and vice versa, in neuronal cell systems (33,104) or in rodents (26, 196) . This well-established functional relationship between XBP1 and the BDNF-TrkB pathway and the role of BDNF as a synaptogenic molecule in synaptic plasticity and synaptic growth should be fully taken advantage of and translated into effective therapies for AD pathology. However, this has been challenging due to several factors. For instance, use of AAV in the clinic has proven difficult due to host immunogenicity to the virus and limited biodistribution (197, 198) . More recent approaches utilizing human mesenchymal stem cells (MSCs) that have been genetically engineered to produce BDNF have shown beneficial outcomes in a Huntington disease model (199) . Importantly, some pharmaceutical companies, namely Atherys, SanBio and Brain Storm Therapeutics, finalized several MSC therapy-based phase II clinical trials involving ischemic stroke and amyotrophic lateral sclerosis patients and reported no adverse effects whatsoever (200) . Furthermore, modulating the IRE1α-XBP1 pathway with small-molecule compounds could be a promising approach for disease therapy (201) , since various studies have reported that XBP1 protects against oligomeric forms of prion protein or α-synuclein (167, (202) (203) (204) . Nonetheless, the majority of these molecules are inhibitors that selectively Indeed, conventional wisdom holds that an increase in Aβ load damages neuronal networks composed of memory engram cells. Therefore, the intuitive reasoning is that reducing Aβ levels should protect synapses, ameliorate neuronal plasticity and translate into beneficial effects on memory function. Thus, interventions that ameliorate spine density and plasticity also boost memory function (170) (171) (172) . Conversely, manipulations that reduce neuronal connectivity and spine density subsequently alter memory (173, 174) . Therefore, targeting mechanisms that could stabilize and protect or repair and reestablish neuronal contacts and at the same time reduce Aβ levels could be an optimal and efficacious strategy against AD pathology, as it was in an animal model (19) . However, one should not overlook evidence that Aβ has many physiological functions through regulation of synaptic activity (for review, see (175) ) and control of genes as a transcription factor (44, 45, 48) . On this basis, XBP1 has the advantage of ameliorating neuronal plasticity and connectivity through both Aβ-dependent and -independent pathways, leading to an overall amelioration of memory function (19) . Giving hope to future efforts, even partial expression of XBP1 has benefits, since only about 60% of neurons were infected in the CA1 and dentate gyrus (19) , which is typical for this type of gene therapy procedure (13, 19, 176, 177) . This also supports the idea that it is not necessary to normalize molecular alterations in every cell and brain region to significantly improve memory, as long as there are enough neurons to form active networks supporting essential brain functions. However, this type of approach needs be associated with effective tools to allow early diagnosis in the clinic, which currently are sorely lacking. Hence, researchers have focused on means to specifically promote synaptogenesis and/or spinogenesis in a subset of neurons or confined areas of the brain through diverse approaches, including oral or peripheral administration of molecules (170, (178) (179) (180) (181) (182) (183) , optogenetic activation (21,58,184-186), epigenetic Therapeutic implications of the Concept that XBP1 Protects Against AD-like Pathology AD has profound effects on patients and families and also represents a tremendous financial burden on the health care system. AD and Parkinson's disease, the two most prevalent neurodegenerative diseases, are estimated to have cost over $600 billion worldwide in 2010 alone. This is staggering, particularly in light of predictions that the number of worldwide AD cases will triple by 2050. Despite many years of research and advancements in basic and clinical research, there is no effective cure to treat neurological disorders associated with aging. Therefore, now more than ever, there is an urgent need to develop new and effective treatments for AD. Typically, two therapeutic approaches can be envisioned to tackle the conundrum of a given pathology: (1) the disease-modifying therapy or toxin-reducing approach targets the etiology of a disease and relies on early intervention to counteract the adverse effects of a given toxin, with the goal of significantly slowing or halting the course of the disease; and (2) the symptomatic therapy or palliative approach intervenes later on in the syndrome to transiently and mildly ameliorate symptoms and relieve pain and discomfort, with no effect whatsoever on the underlying causes and progression of the disease. Therefore, it is evident that a toxin-reducing approach could have better outcomes in AD pathology, which presents multiple clinical signs associated with complex cellular and network alterations. However, it is extremely challenging in general to start an early intervention for a given neurodegenerative disease due to the lack of reliable and sensitive biomarkers. At the time of diagnosis, clinical signs and symptoms are usually apparent, and an effective therapy would require combining symptomatic and disease-modifying approaches. Synaptic failure is a predominant feature in AD, and alteration of neuronal connectivity and spine loss are correlated with memory performance (168, 169) . the timing of the intervention. Indeed, the former study was conducted on earlystage AD patients, whereas the latter involved severe AD cases.
humans (232) . However, other clinical trials failed to report beneficial effects of quercetin on cognitive function (233) . This discrepancy might be explained by block the IRE1α-XBP1 pathway (205, 206) because of its implication in several cancer pathologies, including breast (62) and pancreatic (207) cancers. Although there has not been extensive effort to identify compounds that specifically activate XBP1, quercetin, a flavonol commonly found in vegetables, fruits, nuts and grains in association with sugars, phenolic acids and alcohols, was identified as a compound that activates the RNase activity of IRE1α on XBP1 splicing/activation and elicits a number of signaling pathways (208) . For instance, quercetin attenuates glutamate-mediated excitotoxicity caused by excessive and dysregulated activation of glutamate receptors and/or transporters (209) . This is an important observation, since evidence suggests that glutamate-induced excitotoxicity contributes to the neuronal injury and dysfunction in AD (210) . Indeed, chronic exposure of organotypic hippocampal slices to oligomeric Aβ caused excitotoxicity through an increase of glutamate levels in and around the synaptic cleft, resulting in desensitization of glutamate receptors and altered synaptic plasticity (211, 212) . It should be noted that memantine, an uncompetitive N-methyl-d-aspartate (NMDA) antagonist, protected against axon neurodegeneration and glutamate-induced excitotoxicity caused by Aβ peptide (213) and ameliorated symptoms in human AD (214) . Another interesting feature of quercetin is its capacity to inhibit tau hyperphosphorylation, through SIRT1 (215, 216) or alternate pathways (217, 218) , that occurs primarily in vulnerable brain regions in AD and other tauopathies (89, 219, 220) . Quercetin also displays antiamyloidogenic properties, illustrated by its ability to reduce BACE1 and Aβ levels in mice (217) , prevent Aβ aggregation (221, 222) , promote autophagy (221, 223) and bind to BACE1 catalytic core as an inhibitor (224) . On the other hand, quercetin enhances the effect of neurotrophic factors such as NGF (225) and BDNF (226) to foster neuronal survival and neurite outgrowth, with tangible amelioration of memory function in animal models of AD (227) (228) (229) (230) (231) and in In parallel, XBP1 can be locally synthetized within dendrites through SPRCs and transported into the nucleus to activate transcription of BDNF, Kalirin-7 and a myriad of other genes that are crucial for the survival and plasticity of neurons. mBDNF is released at synapses and activates TrkB receptors to recruit XBP1 and Kalirin-7, which controls spinogenesis through Rho-GTPases RAC1 and PAK1, resulting in a positive activation loop. BDNF signaling also regulates synaptic transmission through control of neurotransmitter release at presynaptic terminals. Abbreviations: AMPA(R), α-amino-3-hydroxy- 
CONCLUsiON
Collectively, there is overwhelming evidence that promoting the BDNF→ XBP1→Kalirin-7 axis produces substantial protective effects on crucial neuronal circuitry involved in memory function by acting through both amyloid-dependent and -independent mechanisms. However, an important aspect to consider, besides proving a therapeutic concept in animal models and generating a drug to effectively translate that concept to clinics, is the challenge to efficaciously deliver a molecule to the brain due to constraints of bioavailability and the blood-brain barrier. In that regard, nanoparticle-based drug engineering (234) and/or MSC-based therapy (200) , if proved efficient, could help overcome a rampant problem encountered in the pharmaceutical industry in general and lead to clinical trials with more positive outcomes. Hence, XBP1 and downstream pathways (see Figure 1 ) merit aggressive and thorough exploration as genuine therapeutic targets that could pave the way for more effective disease-modifying therapies in AD pathology.
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